LON:NCYT

Novacyt (NCYT) Share Forecast, Price & News

GBX 40.10

-1.78 (-4.24%)

(As of 04:34 PM ET)

Compare

Today's Range: 40.10
▼
42.65
50-Day Range: 39.45
▼
58
52-Week Range: 38.20
▼
179.95

Volume: 36,933 shs
Average Volume: 193,305 shs
Market Capitalization: £28.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About Novacyt (LON:NCYT) Stock

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Receive NCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter.

NCYT Stock News Headlines

May 26, 2023 | actusnews.com

Publication of Annual Report and AGM voting

January 30, 2023 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): DHSC Claim Update – Trial Date Listed

June 8, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

January 26, 2023 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group") Full Year 2022 Trading Update

December 7, 2022 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Non-Executive Director Change

December 6, 2022 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of genesig® COVID-19 3G PCR Test in the UK Under CTDA Legislation

November 10, 2022 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Directorate Change

October 26, 2022 | proactiveinvestors.com

Novacyt gains UK approval for its multiplex PCR test for detection of winter viruses

June 8, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

October 26, 2022 | proactiveinvestors.com

Novacyt approved for COVID and winter viruses PCR test

October 10, 2022 | thetimes.co.uk

Your three-minute digest - The Times

October 10, 2022 | marketscreener.com

Novacyt Faces $150 Million Legal Claim For Inconsistent COVID-19 Testing Results In UK - Marketscreener.com

October 9, 2022 | thetimes.co.uk

Novacyt subject to legal claim after 'troubling' Covid test results - The Times

October 6, 2022 | businesswire.com

Outlook on the High-Resolution Melting Analysis Global Market to 2027 - Featuring Agilent Technologies, Azura Genomics, Illumina and Novacyt Among Others - ResearchAndMarkets.com - Business Wire

October 1, 2022 | seekingalpha.com

Novacyt S.A. 2022 Q2 - Results - Earnings Call Presentation (OTCMKTS:NVYTF) - Seeking Alpha

September 29, 2022 | morningstar.co.uk

EARNINGS UPDATES: Volvere says interim performance... - Morningstar

September 29, 2022 | marketwatch.com

Novacyt 1H Pretax Loss Narrowed Despite Major Revenue Decline - MarketWatch

September 29, 2022 | businesswire.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results - Business Wire

September 29, 2022 | finance.yahoo.com

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results

September 21, 2022 | prnewswire.com

Rapid Plasma Reagin Test Market to observe USD 46.28 Mn incremental growth -- Driven by increasing incidence of syphilis - PR Newswire

August 31, 2022 | law360.com

UK Gov't Sues COVID-19 Test Designer For £135M - Law360

August 12, 2022 | finance.yahoo.com

Global Organ Transplant Diagnostics Market to 2031 - Featuring Abbott Laboratories, ARUP Laboratories, BAG Health Care and bioMerieux Among Others - Yahoo Finance

August 10, 2022 | businesswire.com

Outlook on the Organ Transplant Diagnostics Global Market to 2031 - High Demand for Molecular Diagnostic Tests is Driving Growth - ResearchAndMarkets.com - Business Wire

August 6, 2022 | morningstar.co.uk

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim - Morningstar

August 4, 2022 | marketwatch.com

Novacyt Launches New Covid-19 PCR Assays - MarketWatch

August 4, 2022 | businesswire.com

Launch of Novacyt's first fully lyophilised PROmate® assays - Business Wire

July 28, 2022 | lse.co.uk

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee | Financial News - London South East

See More Headlines

NCYT Price History

30 days | 90 days | 365 days | Advanced Chart

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:NCYT
CUSIP: N/A
CIK: N/A
Web: www.novacyt.com
Phone: 33 1 39 46 51 04
Fax: N/A
Employees: 174
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-22,200,000.00
Net Margins: -122.29%
Pretax Margin: N/A
Return on Equity: -17.27%
Return on Assets: -6.06%

Debt

Debt-to-Equity Ratio: 0.76
Current Ratio: 5.25
Quick Ratio: 4.46

Sales & Book Value

Annual Sales: £21.04 million
Price / Sales: 1.35
Cash Flow: GBX 69.09 per share
Price / Cash Flow: 0.58
Book Value: GBX 163 per share
Price / Book: 0.25

Miscellaneous

Outstanding Shares: 70,630,000
Free Float: N/A
Market Cap: £28.32 million
Optionable: Not Optionable
Beta: -2.22

Key Executives

Mr. James Martin McCarthy (Age 57)
CFO, Acting CEO, Company Sec. & Director
Comp: $361.66k

Bryan Close
Chief Operations Officer

Ms. Wendy Karban
Group HR Mang.

Mr. David Franks
Chief HR Officer

Paul Oladimeji
Group Head of R&D

Mr. Gérald Ulrich
Chief Exec. Officer of Bus. Devel.

Mr. Steve Gibson
Group Financial Controller

Key Competitors

View All Competitors

Insiders

James Wakefield
Bought 7,000 shares on 7/7/2022
Total: £819,000.00 ($117.00/share)

View All Insider Transactions

NCYT Stock - Frequently Asked Questions

How have NCYT shares performed in 2023?: Novacyt's stock was trading at GBX 113 on January 1st, 2023. Since then, NCYT shares have decreased by 64.5% and is now trading at GBX 40.10.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Novacyt own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN).
What is Novacyt's stock symbol?: Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."
How do I buy shares of Novacyt?: Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Novacyt's stock price today?: One share of NCYT stock can currently be purchased for approximately GBX 40.10.
How much money does Novacyt make?: Novacyt (LON:NCYT) has a market capitalization of £28.32 million and generates £21.04 million in revenue each year. The company earns £-22,200,000.00 in net income (profit) each year or GBX (0.32) on an earnings per share basis.
How many employees does Novacyt have?: The company employs 174 workers across the globe.
How can I contact Novacyt?: The official website for the company is www.novacyt.com. The company can be reached via phone at 33 1 39 46 51 04.

This page (LON:NCYT) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial